Menu
Search
|

Menu

Close
X

Astellas Pharma Inc 4503.T (Tokyo Stock Exchange)

1,758.00 JPY
+2.00 (+0.11%)
As of 2:00 AM EDT
chart
Previous Close 1,756.00
Open 1,758.50
Volume 7,110,200
3m Avg Volume 7,781,993
Today’s High 1,772.50
Today’s Low 1,746.00
52 Week High 1,786.00
52 Week Low 1,331.50
Shares Outstanding (mil) 1,979.82
Market Capitalization (mil) 3,476,570.00
Forward P/E 21.70
Dividend (Yield %) 19.00 ( 2.05 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 12 analysts

KEY STATS

Revenue (mm, JPY)
FY18
1,300,316
FY17
1,311,665
FY16
1,372,706
FY15
1,247,259
EPS (JPY)
FY18
80.931
FY17
103.443
FY16
89.554
FY15
61.379
*Note: Units in Millions of Yen
**Note: Units in Yen

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.70
33.54
Price to Sales (TTM)
vs sector
2.67
8.28
Price to Book (MRQ)
vs sector
2.74
4.21
Price to Cash Flow (TTM)
vs sector
15.15
22.70
Total Debt to Equity (MRQ)
vs sector
4.49
17.68
LT Debt to Equity (MRQ)
vs sector
3.90
13.20
Return on Investment (TTM)
vs sector
11.55
13.09
Return on Equity (TTM)
vs sector
12.97
15.10

EXECUTIVE LEADERSHIP

Yoshihiko Hatanaka
Chairman of the Board, Chairman of the Board of Directors, Representative Director, Since 2018
Salary: --
Bonus: --
Kenji Yasukawa
President, Chief Executive Officer, Representative Director, Since 2018
Salary: --
Bonus: --
Chikashi Takeda
Chief Financial Officer, Executive Officer, Since 2017
Salary: --
Bonus: --
Bernhardt Zeiher
President - Development, Chief Medical Officer, Since 2018
Salary: --
Bonus: --
Fumiaki Sakurai
Chief Administrative Officer, Chief Ethics & Compliance Officer, Executive Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Astellas Pharma Inc. Headquarter
2-5-1, Nihombashihon-cho
CHUO-KU   TKY   103-8411

Phone: +813.32443000

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

SPONSORED STORIES